Medesis Pharma S.A. (ALMDP.PA)
EUR 0.34
(-2.86%)
EUR 0.34
(-2.86%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.92 Million EUR | 0.56% |
| 2022 | 1.91 Million EUR | -55.72% |
| 2021 | 4.32 Million EUR | 416.33% |
| 2020 | 837.91 Thousand EUR | 17.35% |
| 2019 | 714 Thousand EUR | -56.03% |
| 2018 | 1.62 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 1.72 Million EUR | 0.0% |
| 2023 FY | 1.92 Million EUR | 0.56% |
| 2023 Q4 | 1.92 Million EUR | 0.0% |
| 2023 Q3 | 1.92 Million EUR | 11.81% |
| 2023 Q1 | 1.72 Million EUR | -10.07% |
| 2022 Q4 | 1.91 Million EUR | 0.0% |
| 2022 Q3 | 1.91 Million EUR | -36.16% |
| 2022 FY | 1.91 Million EUR | -55.72% |
| 2022 Q2 | 3 Million EUR | 0.0% |
| 2022 Q1 | 3 Million EUR | -30.64% |
| 2021 Q3 | 4.32 Million EUR | -25.25% |
| 2021 Q2 | 5.78 Million EUR | -0.0% |
| 2021 Q1 | 5.78 Million EUR | 590.76% |
| 2021 Q4 | 4.32 Million EUR | 0.0% |
| 2021 FY | 4.32 Million EUR | 416.33% |
| 2020 Q2 | 601 Thousand EUR | 0.0% |
| 2020 FY | 837.91 Thousand EUR | 17.35% |
| 2020 Q4 | 837.91 Thousand EUR | 0.0% |
| 2020 Q3 | 837.91 Thousand EUR | 39.42% |
| 2019 FY | 714 Thousand EUR | -56.03% |
| 2018 FY | 1.62 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | 86.905% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 99.411% |
| Adocia SA | 24.95 Million EUR | 92.281% |
| Aelis Farma SA | 26.28 Million EUR | 92.67% |
| Biophytis S.A. | 11.93 Million EUR | 83.861% |
| Advicenne S.A. | 12.4 Million EUR | 84.474% |
| genOway Société anonyme | 31.84 Million EUR | 93.95% |
| IntegraGen SA | 8 Million EUR | 75.922% |
| Neovacs S.A. | 47.53 Million EUR | 95.947% |
| NFL Biosciences SA | 3.97 Million EUR | 51.485% |
| Plant Advanced Technologies SA | 14.91 Million EUR | 87.083% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | 48.587% |
| Sensorion SA | 46.49 Million EUR | 95.857% |
| Theranexus Société Anonyme | 7.23 Million EUR | 73.385% |
| TME Pharma N.V. | 2.49 Million EUR | 22.668% |
| Valbiotis SA | 33.24 Million EUR | 94.206% |
| TheraVet SA | 7.53 Million EUR | 74.432% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 94.539% |
| argenx SE | 4.11 Billion EUR | 99.953% |
| BioSenic S.A. | 9.55 Million EUR | 79.848% |
| Celyad Oncology SA | 16.28 Million EUR | 88.169% |
| DBV Technologies S.A. | 165.65 Million USD | 98.837% |
| Galapagos NV | 4.35 Billion EUR | 99.956% |
| Genfit S.A. | 173.87 Million EUR | 98.892% |
| GeNeuro SA | 6.31 Million EUR | 69.486% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 95.96% |
| Innate Pharma S.A. | 184.19 Million EUR | 98.954% |
| Inventiva S.A. | 69.13 Million EUR | 97.214% |
| MaaT Pharma SA | 42.93 Million EUR | 95.513% |
| MedinCell S.A. | 36.94 Million EUR | 94.786% |
| Nanobiotix S.A. | 93.89 Million EUR | 97.948% |
| Onward Medical N.V. | 43.62 Million EUR | 95.585% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 98.198% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 97.648% |
| Oxurion NV | 6.55 Million EUR | 70.59% |
| Pharming Group N.V. | 426.33 Million EUR | 99.548% |
| Poxel S.A. | 4.82 Million EUR | 60.059% |
| GenSight Biologics S.A. | 9.08 Million EUR | 78.801% |
| Transgene SA | 45.21 Million EUR | 95.74% |
| Financière de Tubize SA | 1.92 Billion EUR | 99.9% |
| UCB SA | 15.53 Billion EUR | 99.988% |
| Valneva SE | 469.39 Million EUR | 99.59% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 93.752% |